Health & Fit: Moderna Gives WHO’s mRNA Hub Some Help, Pfizer Snubs Request

COVID: Humboldt County reports two new deaths, five new hospitalizations, 181 new cases in seven day period

  COVID: Humboldt County reports two new deaths, five new hospitalizations, 181 new cases in seven day period Aug. 3—The following is a release from the Humboldt County Joint Information Center: Humboldt County Public Health reported today the death of a resident in their 70s as well as one aged 80 or older. Five new hospitalizations including four residents in their 70s and one aged 80 or older were also reported. An additional 119 confirmed positive cases of COVID-19 were announced as well as 62 new probable cases for the period between Tuesday, July 26, and Tuesday, Aug. 2. The total number of confirmed cases in the county stands at 20,732. An additional 4,535 cases are reported as probable.* Starting Monday, Aug.

(Bloomberg) -- Moderna Inc. has allowed its Covid-19 vaccine to be used in a World Health Organization effort to develop mRNA shots that would increase production and access for poor countries.

A healthcare worker selects a vial of the Moderna vaccine for Covid-19 at a vaccination center in Munich, Germany, on Thursday, Dec. 2, 2021. Germany is poised to clamp down on people who aren’t vaccinated against Covid-19 and drastically curtail social contacts to ease pressure on increasingly stretched hospitals. © Bloomberg A healthcare worker selects a vial of the Moderna vaccine for Covid-19 at a vaccination center in Munich, Germany, on Thursday, Dec. 2, 2021. Germany is poised to clamp down on people who aren’t vaccinated against Covid-19 and drastically curtail social contacts to ease pressure on increasingly stretched hospitals.

Most Read from Bloomberg

  • Bezos Loses Spot as World’s Second-Richest Person to Adani
  • Turkey Seeks to Be First NATO Member to Join China-Led SCO
  • What to Watch as Commodities Traders Prepare for Powell
  • Business Class for $20,000 Means Staff Fly Coach or Not at All
  • Ukraine Latest: Biden Warns Putin; Nuclear Plant Gets Grid Power

Afrigen Biologics & Vaccines, a South African biotechnology company working with the WHO, has used the Moderna vaccine in comparison studies in mice to test the effectiveness of its own shots, said Petro Terblanche, Afrigen’s managing director.

COVID: Humboldt County reports three new hospitalizations, 255 new cases in seven day period

  COVID: Humboldt County reports three new hospitalizations, 255 new cases in seven day period Aug. 17—The following is a release from the Humboldt County Joint Information Center: Humboldt County Public Health reported today three new hospitalizations including a resident in their 50s, one in their 70s and one aged 80 or older. No new deaths were reported. An additional 181 confirmed positive cases of COVID-19 were announced as well as 74 new probable cases for the period between Tuesday, Aug. 9, and Tuesday, Aug. 16. The total number of confirmed cases in the county stands at 21,222. An additional 4,738 cases are reported as probable.* Local vaccination data has been updated on the COVID-19 Data Dashboard.

Demand for Covid shots has slowed across the world as more recent variants of the virus have caused milder illness, yet many people in low- and middle-income countries like South Africa remain unvaccinated and vulnerable to the potentially lethal disease. With Moderna’s help, Afrigen is aiming to develop a shot that may be manufactured by at least 15 production facilities around the globe under the aegis of the WHO’s mRNA Vaccine Technology Transfer Hub in Cape Town.

Moderna didn’t supply the vaccine directly. It allowed the vaccine to be provided by the French government after a request from the United Nations-backed Medicines Patent Pool, according to Marie-Paule Kieny, the pool’s chair. Pfizer Inc. refused a similar request because it didn’t regard the need as urgent, she said.

Moderna sues Pfizer for allegedly copying its COVID-19 vaccine technology

  Moderna sues Pfizer for allegedly copying its COVID-19 vaccine technology Moderna sues Pfizer for allegedly copying its COVID-19 vaccine technology Moderna is taking Pfizer and BioNTech to court, accusing the rival drugmakers of patent infringement over their COVID-19 vaccine. The company said Friday it has filed patent infringement lawsuits against Pfizer and BioNTech in Massachusetts and in Germany, alleging the companies copied its mRNA technology to develop their own coronavirus vaccine and thereby infringed on patents filed by Moderna between 2010 and 2016.

Read More:
Moderna Shot Copied by WHO’s Africa Hub May Be Made Globally Pfizer’s African Partner Produces First Doses of Covid Shots S. Africa Plans to Make mRNA Covid-19 Shots Under WHO Deal

Moderna and the partnership of Pfizer and BioNTech SE have come under increased pressure to allow factories in poorer countries to produce their vaccines after the world’s richest nations raced to inoculate their populations while barely any vaccines were available in large parts of Africa.

More Support Needed

“Since the start of the pandemic Pfizer has received many requests to collaborate on studies and other initiatives from many different worthy sources,” Pfizer said in a response to questions. “Unfortunately, it is impossible to support them all and our focus remains on delivering as per our existing supply agreements with governments.”

Moderna declined to comment.

Pfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuit

  Pfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuit Pfizer 'surprised' by Moderna COVID-19 vaccine patent lawsuitIn two lawsuits filed in U.S. federal court, and Germany where BioNTech is based, Moderna said it is seeking monetary damages for Pfizer/BioNTech's alleged use of its technology in countries where it is enforcing its patents — that excludes 92 low- and middle-income countries. Moderna is only asking for damages tied to alleged infringement that occurred after March 7.

France has supported the mRNA hub, giving it 20 million euros ($20 million) in assistance so far, said Kieny. The WHO’s mRNA hub has a more ambitious plan, with the production of a vaccine designed by Afrigen to take place at factories in countries including South Africa, Argentina, Ukraine and Bangladesh.

The early-stage trials of Afrigen’s shot in mice produced “a strong immune response,” the company said. Moderna placed some conditions on the use of its vaccine in the studies, Terblanche said, declining to elaborate.

Still, Afrigen may need further assistance from Moderna or Pfizer, including allowing the use of vaccine for comparative human trials that are expected to start by May. That request is expected in coming weeks, Kieny said.

Ultimately the WHO plans to follow the production of a Covid-19 vaccine with an attempt to develop inoculations for neglected diseases that plague the citizens of poor countries such as tuberculosis, HIV-AIDS, some forms of cancer and hemorrhagic fevers such as Ebola, Lassa fever and the Marburg virus.

Most Read from Bloomberg Businessweek

Moderna Sues Pfizer and BioNTech Over Covid Vaccine

  Moderna Sues Pfizer and BioNTech Over Covid Vaccine In a personal essay, Amy Gruenhut shares how she was diagnosed with viral encephalitis — inflammation of the brain — that left her fighting for her life

  • The Global Race to Hike Rates Tilts Economies Toward Recession
  • The Biggest Copper Mine in the US Stalled in Dispute Over Sacred Ground
  • It’s White-Collar Jobs That Are at Risk in the Next Recession
  • Chinese Manufacturers Get Around US Tariffs With Some Help From Mexico

©2022 Bloomberg L.P.

Pfizer Starts Pivotal Phase 3 Study of mRNA-Based Influenza Vaccine .
Pfizer Inc (NYSE: PFE) has dosed the first participants in the Phase 3 trial of its quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults. Influenza annually causes 140,000 to 710,000 hospitalizations, 12,000 to 52,000 deaths, and about $25 billion in economic loss in the U.S. The quadrivalent modRNA vaccine candidate will encode World Health Organization recommended strains for the Northern Hemisphere 2022-23 cell culture- or recombinant-based influenza vaccines.

See also